Genfit Company Description
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases.
The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis.
It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA.
The company was incorporated in 1999 and is headquartered in Loos, France.
| Country | France |
| Founded | 1999 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 180 |
| CEO | M. Prigent |
Contact Details
Address: Parc EurasantE Loos, 59120 France | |
| Phone | 33 3 20 16 40 00 |
| Website | genfit.com |
Stock Details
| Ticker Symbol | GNFTY |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| M. Prigent | Chief Executive Officer |
| Thomas Baetz | Chief Financial Officer |
| Pascal Caisey | Chief Operating Officer |
| Jean-Christophe Marcoux | Head of Investor Relations |